JP2020510061A - ピラゾロクロロフェニル化合物、組成物及びその使用方法 - Google Patents

ピラゾロクロロフェニル化合物、組成物及びその使用方法 Download PDF

Info

Publication number
JP2020510061A
JP2020510061A JP2019550583A JP2019550583A JP2020510061A JP 2020510061 A JP2020510061 A JP 2020510061A JP 2019550583 A JP2019550583 A JP 2019550583A JP 2019550583 A JP2019550583 A JP 2019550583A JP 2020510061 A JP2020510061 A JP 2020510061A
Authority
JP
Japan
Prior art keywords
alkyl
compound
group
pharmaceutically acceptable
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019550583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510061A5 (enExample
Inventor
ザック，マーク
ロメロ，エフ・アンソニー
ユエン，ポ−ワイ
ハナン，エミリー・ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2020510061A publication Critical patent/JP2020510061A/ja
Publication of JP2020510061A5 publication Critical patent/JP2020510061A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2019550583A 2017-03-14 2018-03-13 ピラゾロクロロフェニル化合物、組成物及びその使用方法 Ceased JP2020510061A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017076598 2017-03-14
CNPCT/CN2017/076598 2017-03-14
PCT/EP2018/056129 WO2018166993A2 (en) 2017-03-14 2018-03-13 Pyrazolochlorophenyl compounds, compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2020510061A true JP2020510061A (ja) 2020-04-02
JP2020510061A5 JP2020510061A5 (enExample) 2021-04-22

Family

ID=61655767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550583A Ceased JP2020510061A (ja) 2017-03-14 2018-03-13 ピラゾロクロロフェニル化合物、組成物及びその使用方法

Country Status (5)

Country Link
US (2) US20200002346A1 (enExample)
EP (1) EP3596072B1 (enExample)
JP (1) JP2020510061A (enExample)
CN (1) CN110494434B (enExample)
WO (1) WO2018166993A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200010390A (ko) 2017-05-22 2020-01-30 에프. 호프만-라 로슈 아게 치료 화합물 및 조성물, 및 이의 사용 방법
JP7657740B2 (ja) 2019-06-18 2025-04-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｊａｋキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
WO2022256358A1 (en) * 2021-06-03 2022-12-08 Genentech, Inc. Process for preparing medicaments

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006070202A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
JP2007516194A (ja) * 2003-07-03 2007-06-21 アステックス、セラピューティックス、リミテッド 医薬化合物
JP2012532112A (ja) * 2009-07-02 2012-12-13 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物及び方法
WO2015177326A1 (en) * 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
JP2016535772A (ja) * 2013-11-08 2016-11-17 武田薬品工業株式会社 自己免疫疾患治療のためのピラゾール

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
JP4486817B2 (ja) 2001-12-20 2010-06-23 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト １，４−ジヒドロ−１，４−ジフェニルピリジン誘導体
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
EP1968579A1 (en) * 2005-12-30 2008-09-17 Astex Therapeutics Limited Pharmaceutical compounds
WO2008001101A2 (en) * 2006-06-29 2008-01-03 Astex Therapeutics Limited Pharmaceutical combinations
JP5523829B2 (ja) * 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
US20100048557A1 (en) 2008-06-20 2010-02-25 Bing-Yan Zhu Triazolopyridine JAK Inhibitor Compounds and Methods
JP5769199B2 (ja) * 2008-10-31 2015-08-26 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物と方法
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP3416967B1 (en) * 2016-02-18 2022-02-09 F. Hoffmann-La Roche AG Therapeutic compounds, compositions and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516194A (ja) * 2003-07-03 2007-06-21 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2006070202A1 (en) * 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives having kinase modulating activity
JP2012532112A (ja) * 2009-07-02 2012-12-13 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物及び方法
JP2016535772A (ja) * 2013-11-08 2016-11-17 武田薬品工業株式会社 自己免疫疾患治療のためのピラゾール
WO2015177326A1 (en) * 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"RN 1348439-69-9, 1348366-33-5, 1348342-66-4, 1348042-57-8, 1347970-24-4, 1347873-72-6 REGISTRY", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7022000927, 4 December 2011 (2011-12-04), ISSN: 0004965067 *
"RN 1349237-47-3, 1348949-82-5 REGISTRY", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7022000928, 5 December 2011 (2011-12-05), ISSN: 0004965066 *
"RN 1825504-02-6 REGISTRY", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7022000929, 9 December 2015 (2015-12-09), ISSN: 0004965065 *
"RN 1935725-26-0 REGISTRY", DATABASE REGISTRY [ONLINE] RETRIEVED FROM STN, JPN7022000930, 20 June 2016 (2016-06-20), ISSN: 0004965064 *

Also Published As

Publication number Publication date
WO2018166993A2 (en) 2018-09-20
US20200002346A1 (en) 2020-01-02
WO2018166993A3 (en) 2019-02-07
CN110494434B (zh) 2022-05-24
US20210179626A1 (en) 2021-06-17
US11649241B2 (en) 2023-05-16
EP3596072B1 (en) 2022-06-22
CN110494434A (zh) 2019-11-22
EP3596072A2 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
RU2769696C2 (ru) Терапевтические соединения и композиции и способы их применения
JP7228318B2 (ja) 処置用化合物及び組成物、並びにその使用方法
JP6914933B2 (ja) ヤヌスキナーゼ、並びにその組成物及びその使用
US11649241B2 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
US20230206644A1 (en) Pyrazolopyrimidine compounds as jak inhibitors
US20200270248A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
JP2022537964A (ja) Ｊａｋキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用
HK40093207A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK40017827A (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
HK40019825A (en) Therapeutic compounds and compositions, and methods of use thereof
HK40009645B (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof
HK40009645A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210308

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240227